Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20496-20506

  Sun, Wei ^a,b   Jiang, Yi Zhou ^a,b   Liu, Yi Rong ^a,b   Ma, Ding ^a,b   Shao, Zhi Ming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer specific survival; Luminal breast cancer; Nomogram; Overall survival

Indexed keywords

ADULT; AGED; ARTICLE; BLACK PERSON; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CAUCASIAN; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; NOMOGRAM; ONSET AGE; OVERALL SURVIVAL; PROBABILITY; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; TUMOR VOLUME; VALIDATION STUDY; ADOLESCENT; BREAST TUMOR; CASE CONTROL STUDY; LOBULAR CARCINOMA; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NOMOGRAMS; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE; YOUNG ADULT;

EID: 84964699850     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7975     Document Type: Article

References (36)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA 2014; 64:252-271.
2. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA. 2014; 64:52-62.
3. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, et al. Gene expression profiles of human breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:5974-5979.
4. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:10393-10398.
5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology. 2011; 22:1736-1747.
6. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365:1687-1717.
7. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, investigators AL. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet Oncology. 2010; 11:1135-1141.
8. Arimidex TAoiC TG, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. The Lancet Oncology. 2008; 9:45-53.
9. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptorpositive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. The Lancet Oncology. 2011; 12:1101-1108.
10. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 2009; 101:736-750.
11. Mazouni C, Spyratos F, Romain S, Fina F, Bonnier P, Ouafik LH, Martin PM. A nomogram to predict individual prognosis in node-negative breast carcinoma. European journal of cancer. 2012; 48:2954-2961.
12. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. Journal of clinical oncology. 2007; 25:4952-4960.
13. Southern DA, Faris PD, Brant R, Galbraith PD, Norris CM, Knudtson ML, Ghali WA, Investigators A. Kaplan-Meier methods yielded misleading results in competing risk scenarios. Journal of clinical epidemiology. 2006; 59:1110-1114.
14. Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. Journal of clinical oncology. 2013; 31:468-474.
15. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in medicine. 1999; 18:695-706.
16. Korhonen T, Kuukasjarvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A, Pylkkanen L. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast. 2013; 22:1119-1124.
17. Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM. Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clinic proceedings. 2012; 87:1171-1180.
18. Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet. 2011; 378:1707-1716.
19. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer. 1989; 63:181-187.
20. Song Q, Huang R, Li J, Fan J, Zheng S, Zhang B, Yang H, Tang Z, He J, Xie X, Li H, Li J, Qiao Y. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PloS one. 2013; 8:e72175.
21. Orecchia R. Breast cancer: post-mastectomy radiotherapy reduces recurrence and mortality. Nature reviews Clinical oncology. 2014; 11:382-384.
22. van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. Jama. 2012; 307:590-597.
23. Wray CJ, Phatak UR, Robinson EK, Wiatek RL, Rieber AG, Gonzalez A, Ko TC, Kao LS. The effect of age on racerelated breast cancer survival disparities. Annals of surgical oncology. 2013; 20:2541-2547.
24. Newschaffer CJ, Penberthy L, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Archives of internal medicine. 1996; 156:85-90.
25. Liu YR, Jiang YZ, Yu KD, Shao ZM. Different Patterns in the Prognostic Value of Age for Breast Cancer-Specific Mortality Depending on Hormone Receptor Status: A SEER Population-Based Analysis. Annals of surgical oncology. 2015; 22:1102-1110.
26. Cunningham JE, Butler WM. Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast cancer research and treatment. 2004; 88:161-176.
27. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancerspecific survival by race and ethnicity in the United States. Jama. 2015; 313:165-173.
28. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. Journal of clinical oncology. 2006; 24:1342-1349.11.
29. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/.
30. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of statistics. 1988:1141-1154.
31. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American statistical association. 1999; 94:496-509.
32. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009; 20:555-561.
33. Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. Open access available at: http://cranr-projectorg. 2014.
34. Gray B. cmprsk: Subdistribution analysis of competing risks. URL: http://CRANR.2013.
35. Harrell Jr FE. rms: regression modeling strategies. R package version. 2013; 3.6-3.
36. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. Epidemiology. 2009; 20:555-561.